Monthly Archives: October 2012

BayBio Op-ed featured in Xconomy

GM

Gail Maderis, President & CEO of BayBio, recently discussed the strength of Northern California’s biotechnology industry and the BIO Investor Forum in Xconomy: With more than 850 biotechnology companies, the Bay Area is the oldest, largest and most productive life sciences cluster in the world, employing more than 125,000 people in the region. For more than 30 years, this region has led the world in researching and delivering new cures and treatments for debilitating diseases Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of certainty for public exits, subsequent private financings, and even pharma licensing deals are over. IPOs have been out of favor for five years, venture firms are turning away from the sector, and fewer licensing deals are being cut. What is less understood about this uncertain environment is how it has forced management and their venture backers, to not only rethink Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

World Food Day 2012: The Role of Agricultural Biotechnology

food-day-2012

As we celebrate Food Day 2012, it seems the debate around agriculture and food production is more contentious than ever.  Instead of celebrating our abilities to provide for seven billion people on our planet in ways that are more sustainable and productive than ever before, there are still some who want to ridicule our modern food production system. Agricultural biotechnology – one of the most basic tools helping us to better feed, fuel and heal Read More >

Farmer Gene  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Investor Forum – Raring to Go: The Race to Treat Ultra-Rare Diseases

BIO Investor Forum

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline. In anticipation of an even more compelling opportunity, many companies are taking a step beyond and focusing on ultra rare diseases. Last week’s 11th Annual BIO Investor Forum in San Francisco hosted a panel, Raring Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Travels to Brazil to Support the Ecosystem of Innovation

Refinery

Government policies that support innovation are critical as the biotechnology industry seeks to develop innovative healthcare, agricultural, industrial and environmental biotechnology products and provide them to people all around the world. Innovation requires not only scientific research and commercial expertise, but also supportive and dynamic governments that help facilitate long-term growth of the industry. Brazil has recognized the value of innovation in maintaining a robust, diversified economy that can compete in the 21st century, and declared Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,